Can Aspirin Be Given in Patients with Cerebral Microhemorrhages?
Yes, aspirin can be given to patients with cerebral microhemorrhages, though this decision requires careful risk-benefit assessment based on the indication for antiplatelet therapy and the patient's overall cardiovascular risk profile.
Clinical Context and Evidence Base
The relationship between aspirin and cerebral microhemorrhages (CMBs) is nuanced. While CMBs represent markers of cerebral small vessel disease and theoretically increase bleeding risk, the evidence suggests a more complex picture:
Key Evidence from Guidelines
Current stroke guidelines indicate that antiplatelet agents may be reasonable and considered in everyday clinical practice even after intracerebral hemorrhage (ICH), with evidence ranked as level B 1. The ongoing ASPIRING trial is specifically designed to address antiplatelet use (including aspirin) after ICH, recognizing that the high risk of major adverse cardiovascular events (MACE) may outweigh bleeding concerns 1.
Research Evidence on Aspirin and CMBs
The evidence regarding aspirin's relationship with CMBs shows:
Aspirin does not appear to increase CMB size: Animal studies demonstrate that aspirin treatment does not increase microhemorrhage size in either young or aged mice, unlike heparin which did increase hematoma diameter 2
Association vs. causation: While aspirin use is associated with CMBs in stroke-free populations (OR = 2.39 for any CMB, OR = 2.83 for lobar CMBs) 3, one large study of asymptomatic elderly found no significant association between aspirin use and CMBs, even with prolonged use >5 years 4
Modest absolute risk increase: Meta-analysis shows aspirin increases intracranial hemorrhage risk by approximately 2 additional events per 1000 people (RR 1.37) 5
Clinical Decision Algorithm
1. Assess the Indication for Aspirin
- Strong cardiovascular indication (secondary prevention after MI, stroke, or high MACE risk): The benefits likely outweigh risks even with CMBs present
- Primary prevention only: More cautious approach warranted, especially with multiple CMBs
2. Evaluate CMB Burden and Location
- Few CMBs (<5): Generally safe to use aspirin if indicated
- Multiple CMBs (≥5) or lobar location: Higher caution, as lobar CMBs may indicate cerebral amyloid angiopathy with higher hemorrhage risk 6
- Mixed or deep CMBs: Slightly lower concern than lobar
3. Consider Patient-Specific Risk Factors
Higher bleeding risk with aspirin in:
- Asian race/ethnicity 5
- Low body mass index 5
- Age ≥60 years 7
- History of stomach ulcers or bleeding 7
- Concurrent anticoagulation 7
4. Optimize Dosing
- Use the lowest effective dose: In patients at high risk for hemorrhagic transformation, lower aspirin doses (e.g., 100 mg vs. 300 mg) may reduce risk of parenchymal hematoma 8
- Standard low-dose aspirin (75-100 mg daily) is preferred over higher doses
Important Caveats
The presence of CMBs alone should not automatically preclude aspirin use. CMBs are risk markers, not absolute contraindications. The critical question is whether the patient's cardiovascular risk justifies antiplatelet therapy.
Timing matters: After acute ICH, current practice suggests considering antiplatelet resumption, though optimal timing remains under investigation 1. The ASPIRING trial will provide definitive guidance on this question.
Monitor for progression: In patients with CMBs on aspirin, consider periodic imaging to assess for CMB progression, though specific monitoring intervals are not established.
Avoid in specific scenarios: Do not use aspirin if the patient has had allergic reactions to aspirin 7, active bleeding, or ICH secondary to structural causes like aneurysms or arteriovenous malformations 1.
The evidence suggests that the cardiovascular benefits of aspirin often outweigh the modest increase in bleeding risk, even in patients with CMBs, particularly when used for secondary prevention of cardiovascular events.